KIT D816V Biology and Longitudinal Symptom Assessment in Indolent Systemic Mastocytosis

Indolent systemic mastocytosis (ISM) is tightly linked to activating mutations in KIT, most commonly the D816V substitution in the intracellular domain, which drives mast cell survival, activation, and differentiation. This mutation results in constitutive signaling that promotes expansion of the mast cell compartment beyond physiologic requirements. Although KIT D816V was first characterized in advanced variants of systemic mastocytosis, improvements in molecular diagnostics have revealed its presence in more than 95% of patients with ISM, typically restricted to mast cells in indolent disease and extending to additional myeloid lineages in advanced forms. The strong concordance between KIT D816V and clinical mastocytosis, together with the observed reduction in disease manifestations when mutant mast cells are depleted, supports its role as a bona fide disease-driving lesion.

Because ISM is characterized by chronic, fluctuating multisystem symptoms, longitudinal assessment is central to optimal management. Clinicians must routinely evaluate dermatologic (spots, flushing, pruritus), gastrointestinal (diarrhea, abdominal pain, bloating), and neurocognitive (fatigue, “brain fog,” anxiety) domains, as well as major complications such as Hymenoptera venom–induced anaphylaxis. Historically, symptom evaluation relied primarily on unstructured dialogue and physical examination, but there is increasing interest in formal patient-reported outcome (PRO) measures. The Mastocytosis Control Test (MCT), a brief 5‑item patient-completed instrument scored from 0 to 4 per item, was developed to capture disease impact over the preceding 2 weeks and is conceptually analogous to validated tools used in asthma, urticaria, and allergic rhinitis.

Although the MCT has not yet been universally adopted in routine practice, its simplicity makes it an attractive candidate for integration into electronic health records and longitudinal care pathways. Scores can help identify patients whose disease remains poorly controlled and who may warrant escalation of therapy, additional evaluation of comorbidities, or referral to specialized centers. In this video, Akin describes how systematic use of such instruments, in combination with thorough clinical interviewing, may improve the precision of symptom monitoring and provide a more reproducible framework for assessing response to emerging targeted therapies in ISM.